淋巴瘤
小学(天文学)
医学
B细胞
B细胞淋巴瘤
病理
免疫学
抗体
物理
天文
作者
L L Zhang,Chunju Zhou,N Li,Shaojun Huang,Mingduo Zhang,Ling Jin,Jing Yang,Yingzi Zhang,Yanlong Duan
出处
期刊:PubMed
[National Institutes of Health]
日期:2025-08-02
卷期号:63 (8): 901-905
标识
DOI:10.3760/cma.j.cn112140-20241104-00788
摘要
Objective: To investigate the clinical features, pathologic characteristics, treatment and prognosis of primary mediastinal large B-cell lymphoma (PMBCL) in children. Methods: Clinical data including clinical manifestations, treatment, clinical efficacy of 8 cases of childhood PMBCL treated in Beijing Children's Hospital, Capital Medical University from March 2017 to February 2024 were collected retrospectively, the clinical characteristics and prognosis of them were summarized. Results: Among the 8 children, there were 5 males and 3 females. The age at the time of initial diagnosis was 11.0 (10.3, 13.5) years. The first clinical symptoms were cough (8 cases) and stridor (6 cases). The lesions most often involved the mediastinum (8 cases), lungs (5 cases, hilum more often), pericardium (5 cases), and pleura (4 cases). Extra thoracic invasion was present in 4 cases, 7 cases had huge tumor lesions and 7 cases were phase Ⅲ clinical stage. Except for 1 case who underwent surgical resection of the tumor, the remaining 7 cases were treated with DA-EPOCH+R (dose adjusted-etoposide+prednisone+vincristine+cyclo-phosphamide+doxorubicin+rituximab) chemotherapy. The follow-up time was 25.0 (10.5, 43.3) months, with 7 cases in complete and partial metabolism response, 1 case had disease progression. All 8 cases survived. Conclusions: PMBCL is most common in school-age boys and most of them present with huge mediastinal tumor focus. PMBCL expresses B-cell spectrum antigens and weakly expresses CD30.The application of DA-EPOCH+R is effective in the treatment of PMBCL in children.
科研通智能强力驱动
Strongly Powered by AbleSci AI